Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

OBJECTIVE: Previous reports of the RAPID-axSpA trial (NCT01087762) described the efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with axial spondyloarthritis (SpA), including ankylosing spondylitis (AS) and nonradiographic axial SpA. We report efficacy and safety data up to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sieper, J, Landewé, R, Rudwaleit, M, van der Heijde, D, Dougados, M, Mease, P J, Braun, J, Deodhar, A, Kivitz, A, Walsh, J, Hoepken, B, Nurminen, T, Maksymowych, W P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365732/
https://www.ncbi.nlm.nih.gov/pubmed/25470228
http://dx.doi.org/10.1002/art.38973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365732/
https://www.ncbi.nlm.nih.gov/pubmed/25470228
http://dx.doi.org/10.1002/art.38973

Ejemplares similares